|
What AAO attendees learned from a single session devoted to diabetes
|
 At Retina Subspecialty Day during the 2019 AAO meeting, presentations as varied as artificial intelligence, news from the Diabetic Retinopathy Clinical Research Retina Network (DRCR.net), using OCT to predict visual outcomes, and how to manage patients with high-risk nonproliferative diabetic retinopathy without DME were among the highlights.
|
|
Learn more
|
|
|
|
AMD risk phenotypes targeted in direct-to-consumer genetic database
|
 Genetic testing can identify patients with high-risk genotypes for age-related macular degeneration, says Theodore Leng, MD, MS.
|
|
Find out
|
|
|
|
|
|
ADVERTISEMENT
|
|
Be curious. Be excited. Be informed.
|
Novartis is pleased to announce that BEOVU® (brolucizumab-dbll) injection has been approved by the Food and Drug Administration (FDA) and is now available.
 Learn more.
© 2019 Novartis 10/19 BVU-1381297
|
|
|
|
|
RELATED ARTICLES
|
